GSK's Zejula Poised To Take On Lynparza In First-Line Ovarian Cancer

The Phase III PRIMA study in first-line ovarian cancer was positive for progression-free survival in patients regardless of their biomarker status, GSK reported.

Paper plane on white background. Business competition concept. - Image

GlaxoSmithKline PLC's poly ADP-ribose polymerase (PARP) inhibitor Zejula (niraparib) could have an edge over rivals as a first-line maintenance therapy in ovarian cancer based on results from the positive Phase III PRIMA trial in the broad population.

The double-blind, placebo-controlled study met its primary endpoint of a statistically significant improvement in progression free survival for women regardless of their biomarker status, GSK reported on 15 July. AstraZeneca PLC and Merck & Co. Inc.

More from Anticancer

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

 

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.

In Brief: Genmab To Seek FDA Nod For Epkinly In Lymphoma

 

Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

 

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.

More from Therapy Areas

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

 

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By 

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

 

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.